Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
CNY 57.39
(-0.92%)
CNY 57.39
(-0.92%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.56 Billion | 1.44 Billion | 1.29 Billion | 1.03 Billion | 554.63 Million | 559.46 Million |
| Cost of Revenue | 142 Million | 93.13 Million | 83.75 Million | 62.84 Million | 32.34 Million | 31.09 Million |
| Gross Profit | 1.42 Billion | 1.35 Billion | 1.2 Billion | 975.79 Million | 522.28 Million | 528.37 Million |
| Operating Expenses | 898.63 Million | 688.12 Million | 567.5 Million | 499.96 Million | 291.98 Million | 313.85 Million |
| Selling, General and Administrative Expenses | 610.86 Million | 453.03 Million | 443.01 Million | 404.31 Million | 246.26 Million | 278.19 Million |
| Research and Development Expenses | 253.02 Million | 179.94 Million | 78.87 Million | 58.25 Million | 22.78 Million | 18.92 Million |
| Other Expenses | 33.11 Million | 50.18 Million | 269.14 Million | -1.12 Million | -71.21 Thousand | -205.19 Thousand |
| Cost and Expenses | 1 Billion | 781.25 Million | 651.25 Million | 562.81 Million | 324.33 Million | 344.94 Million |
| Operating Income | 576.61 Million | 685.5 Million | 915.75 Million | 485.05 Million | 223.4 Million | 189.62 Million |
| Interest Expense | 4.85 Million | 3.18 Million | 72.68 Thousand | 230.79 Thousand | 532.83 Thousand | 441.64 Thousand |
| Income Tax Expense | 64.77 Million | 85.72 Million | 86.1 Million | 75.89 Million | 36.64 Million | 35.28 Million |
| Earnings before Tax | 573.99 Million | 683.79 Million | 915.57 Million | 483.93 Million | 223.33 Million | 189.42 Million |
| Net Income | 509.21 Million | 598.06 Million | 829.47 Million | 408.04 Million | 186.68 Million | 154.13 Million |
| Earnings Per Share Basic | 3.81 | 4.47 | 6.15 | 3.02 | 1.38 | 1.54 |
| Earnings Per Share Diluted | 3.81 | 4.46 | 6.14 | 3.02 | 1.38 | 1.54 |
| Weighted Average Shares Outstanding | 133.74 Million | 133.93 Million | 134.97 Million | 134.99 Million | 134.99 Million | 100.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 133.74 Million | 133.97 Million | 134.99 Million | 134.99 Million | 134.99 Million | 100.23 Million |
| Gross Margin | 0.91 | 0.94 | 0.94 | 0.94 | 0.94 | 0.94 |
| EBIT Margin | 0.41 | 0.53 | 0.74 | 0.48 | 0.43 | 0.40 |
| Profit Margin | 0.32 | 0.41 | 0.64 | 0.39 | 0.34 | 0.28 |
| EBITDA | 640.61 Million | 728.08 Million | 937.52 Million | 496.42 Million | 233.86 Million | 199.22 Million |
| Earnings Before Tax Margin | 0.37 | 0.47 | 0.71 | 0.47 | 0.40 | 0.34 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 319.29 Million | 425.89 Million | 309.93 Million | 1.56 Billion | 583.47 Million | 355.61 Million |
| Cost of Revenue | 20.3 Million | 51.82 Million | 12.93 Million | 142 Million | 50.63 Million | 22.63 Million |
| Gross Profit | 298.99 Million | 374.06 Million | 297 Million | 1.42 Billion | 532.84 Million | 332.97 Million |
| Operating Expenses | 192.47 Million | 195.15 Million | 128.15 Million | 826.62 Million | 326.09 Million | 206.1 Million |
| Selling, General and Administrative Expenses | 215.29 Million | 176.73 Million | 102.42 Million | - | 261.15 Million | 150.96 Million |
| Research and Development Expenses | 27.88 Million | 18.46 Million | 25.82 Million | - | 62.01 Million | 80.11 Million |
| Other Expenses | -50.7 Million | 44.74 Thousand | 94.42 Thousand | -1.35 Million | -2.92 Million | -15.71 Million |
| Cost and Expenses | 212.77 Million | 246.97 Million | 141.08 Million | 968.63 Million | 376.72 Million | 228.74 Million |
| Operating Income | 111.23 Million | 178.91 Million | 168.84 Million | 598.99 Million | 206.75 Million | 130.4 Million |
| Interest Expense | 1.29 Million | 1.26 Million | 1.4 Million | 4.8 Million | 1.26 Million | 1.18 Million |
| Income Tax Expense | 11.78 Million | 22.07 Million | 22.67 Million | 64.77 Million | 25.68 Million | 9.4 Million |
| Earnings before Tax | 111.13 Million | 179.15 Million | 172.14 Million | 573.99 Million | 165.96 Million | 130.13 Million |
| Net Income | 99.34 Million | 157.08 Million | 149.46 Million | 509.21 Million | 140.27 Million | 120.73 Million |
| Earnings Per Share Basic | 0.76 | 1.19 | 1.12 | - | 1.04 | 0.90 |
| Earnings Per Share Diluted | 0.76 | 1.19 | 1.12 | - | 1.02 | 0.90 |
| Weighted Average Shares Outstanding | 129.89 Million | 132.29 Million | 133.74 Million | 134.65 Million | 134.65 Million | 133.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 129.89 Million | 132.29 Million | 133.74 Million | 134.65 Million | 137.02 Million | 133.76 Million |
| Gross Margin | 0.94 | 0.88 | 0.96 | 0.91 | 0.91 | 0.94 |
| EBIT Margin | 0.35 | 0.48 | 0.58 | - | 0.39 | 0.32 |
| Profit Margin | 0.31 | 0.37 | 0.48 | 0.32 | 0.24 | 0.34 |
| EBITDA | 112.43 Million | 203.21 Million | 178.49 Million | - | 225.5 Million | 114.44 Million |
| Earnings Before Tax Margin | 0.35 | 0.42 | 0.54 | 0.38 | 0.35 | 0.37 |
ACE
MITT-PA
CHEMPLASTS
ACLN
ACESOFT
002037